Nanogen Enters Into Supply and License Agreement With deCode Genetics
Monday April 18, 8:00 am ET
SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of advanced diagnostic products, announced today that it has entered into a supply and license agreement with deCode Genetics to provide a new genomics assay for single nucleotide polymorphism (SNP) discovery, validation and screening. The assay incorporates a full range of Nanogen's products, including the Eclipse® Dark Quencher, new DNA linker technology, modified bases and novel fluorescent dyes, and allows rapid SNP analysis on a large number of patient samples.
"The products and assay that we will provide deCode represent our comprehensive product menu available from the recent merger of Nanogen and Epoch Biosciences," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. "We are pleased deCode has joined our roster of licensing partners eager to tap our growing portfolio of products that enable rapid, high-throughput genetic analysis."
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip® Molecular Biology Workstation, NanoChip® Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website atwww.nanogen.com. |
